Home Healthcare Market Insights Analysis 2020-2027

 The global home healthcare market is anticipated to expand at  8.1% CAGR from 2017 to 2023 (forecast period), according to the latest report by Market Research Future (MRFR). Home healthcare is an increasing viable option being preferred by patients owing to increasing healthcare costs and the burgeoning geriatric population. Home healthcare provides a range of services including physical therapy, speech therapy, occupational therapy, and skilled nursing. The digitization of data has made it simpler for patients to contact physicians and clinicians and gain an accurate diagnosis from the comforts of their home.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/2030

Technological advances in healthcare and diagnosis equipment and government initiatives encouraging home healthcare are likely to fuel market demand in the forthcoming years. Taking a cue from patient demands, players such as Philips have launched wireless solutions. This is evident by the introduction of CarePoint 5.0, a easy-to-use nurse call system for senior citizens in assisted living facilities and bedridden patients recuperating at home. But concerns regarding patient safety can impede market growth.

Home Healthcare Market Overview

The report covers the latest trends affecting the market to provide the most accurate forecasts and predictions. By correlating the historical data with key market dynamics, our analysts can make highly astute projections. MRFR’s report includes a thorough analysis of the global home healthcare market segmented by product, service, software, and region. Trends and opportunities are highlighted coupled with the home healthcare market share of companies as well as their valuation in the market. It analyzes new revenue sources for players and outlines the various strategies implemented by players.

Segment Overview

The global home healthcare market is segmented by product, service, software, and region. Products in the market include therapeutic and testing, screening, and monitoring products. The former is sub-segmented into dialysis equipment, respiratory therapy equipment, IV equipment, insulin delivery devices, wound care products, and others. On the other hand, the latter is segmented into holter and event monitors, pulse oximeters & heart rate monitors, sleep apnea monitors, blood glucose monitors, blood pressure monitors, cholesterol monitoring devices, and others.

Software discussed in the report designed to alleviate patient and hospital troubles include hospice solutions, telehealth solution, agency software, and clinical management systems. Based on services, the market is segmented into skilled nursing services, unskilled care services, respiratory therapy services, rehabilitation therapy services, infusion therapy services, and pregnancy care services.

The segments covered in the report are analyzed with respect to four major regions – North America, Europe, Asia Pacific (APAC), and the Middle East and Africa (MEA), with respective country-level market sizing. The definition and advantages of “home healthcare” is outlined in the report for a comprehensive understanding of the market. The report discusses in detail the various players and their respective strategies to enhance their value chain.

Competitive Landscape

Some of the key players in the home healthcare market include Koninklijke Philips N.V. (The Netherlands), F. Hoffmann-La Roche AG (Switzerland), A&D Company (Japan), Fresenius SE & Co KGaA (Germany), Abbott (U.S.), GE Healthcare (U.S.), McKesson Corporation (U.S.), B. Braun Melsungen AG (Germany), Becton Dickinson Company (U.S.), Omron Corporation (Japan), Medtronic PLC (U.S.), LG Electronics (South Korea), Kinnser Software (U.S.), Apple (U.S.), 3M (U.S.), and others. These players are engaged in partnerships to launch new products in the market and expand their consumer base.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/home-Healthcare-market-2030

Chinese Fibromyalgia Market Foraying into Emerging Economies 2020-2027

 Fibromyalgia syndrome is a condition characterized by widespread musculoskeletal pain. Patients with fibromyalgia may also have muscle stiffness, increased sensitivity to pain, problems with mental processes, fatigue, irritable bowel syndrome (IBS), and others. As symptoms of fibromyalgia syndrome mimic other chronic diseases, therefore its diagnosis takes a long time. According to a study published in Arthritis Research & Therapy journal in 2017, in Taiwan, the risk of coronary heart disease in fibromyalgia patients was 47% higher than in the general population. For fibromyalgia to be diagnosed, the differential diagnosis is most commonly used.  Other diagnostic procedures, such as laboratory evaluations are also used.

Notably, increasing cases of rheumatic diseases and growing geriatric population are the key factors driving the Chinese fibromyalgia market. According to the study published in Aging Clinical and Experimental Research in 2014, fibromyalgia syndrome can affect people of all age group, with the high prevalence in the elderly population as the geriatric population is more vulnerable towards pain, reduced mobility, and sleep disruption. In the general population, the prevalence of fibromyalgia increases by 2% at the age of 20 to 8% at the age of 70.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5630

Growing awareness among the population, and rising incidences of traumatic stress and road accidents are also fueling the market growth. According to a study published in Pain Research and Management journal, in 2014, it was found that physical trauma is followed by fibromyalgia syndrome. In this study, conducted with a specific cohort of individuals involved in a motor vehicle collision, found that 8% of individuals developed widespread chronic pain. Widespread chronic pain characterizes fibromyalgia.

However, difficulty in diagnosis may hinder the growth of the market over the forecast period. Fibromyalgia can’t be easily confirmed as the condition is commonly expressed with many other accompanying chronic disorders such as rheumatic diseases, neurological disorders, mental health problems, and others

Chinese fibromyalgia market growth is expected to grow at a CAGR of 18.7% during the forecast period 2017-2022.

Intended Audience

• Pharmaceutical Companies
• Hospitals & Clinics
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Segmentation

The Chinese fibromyalgia market is segmented on the basis of diagnosis, treatment, and end-user.

On the basis of the diagnosis, the market is classified into laboratory evaluation and presence of central sensitization.

On the basis of the treatment, the market is segmented into targeted treatment and symptomatic treatment.

On the basis of the end-users, the market is segmented into hospitals, clinics, diagnostic centers, and others.

Key Findings

• The Chinese fibromyalgia market is expected to reach USD 3,079.1 million by 2022 at a CAGR of 18.7%
• On the basis of the diagnosis, the laboratory evaluation segment is expected to command the largest market share of 77.2% over the review period, and it is also expected to grow at the fastest CAGR of 19.1% during the forecast period 2017-2022
• On the basis of the treatment, the symptomatic treatment segment is expected to command the largest market share of 68.6% over the review period, and targeted treatment is expected to grow at the fastest CAGR of 19.2% during the forecast period 2017-2022
• South Central China holds the largest share of the Chinese fibromyalgia market and is expected to reach USD 785.3 million by 2022
• North China is the fastest growing market, which is expected to grow at a CAGR of 19.2% over the forecast period 2017-2022

Regional Analysis

South Central China accounted for the major share of the market owing to the rising prevalence of fibromyalgia in this region. Rising cases of chronic rheumatic diseases are also capable of fuelling the fibromyalgia market in China. Prevalence of rheumatoid arthritis is around 0.35%, with the significantly higher rate in Northern China as compared to the Southern part.

The rising healthcare expenditure is also propelling the growth of the market. In China, the total expenditure on health per capita in 2014 was USD 731, as per the World Health Organization (WHO) in 2015. The health expenditure in China grew at a rate of 11.6% per year, suggested by a study published in BMC Health Services Research journal in 2017. This rate is much faster than the growth of the country’s economy, i.e. 9.9% per year.

Key Players

Some of key the players in the market are Pfizer, GlaxoSmithKline, AstraZeneca, Roche, Astellas Pharma, Eli Lilly and Company, Johnson & Johnson Services, Inc., SANOFI, Bayer AG, AbbVie, ALLERGAN, Boehringer Ingelheim, Cephalon, Inc., Vertical Pharmaceuticals, Sunovion Pharms Inc, Jazz Pharmaceuticals, ABBOTT, NOVARTIS, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/chinese-fibromyalgia-market-5630

Sentinel Node Biopsy Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 A sentinel lymph node biopsy is a medical procedure, which involves identification, removal, and examination of the lymph node to verify the presence of cancer cells. Lymph nodes are a part of the lymphatic system which is found throughout the body and is connected to the lymph vessels.  Breast cancer, melanoma, colon cancer, esophageal cancer, head and neck cancer, non-small cell lung cancer, stomach cancer, thyroid cancer are various indications for biopsy. The procedure helps the healthcare provider to determine the stage of cancer, its metastasis in order to plan a line of treatment for the patient.

Browse Sample of the Report  @ https://www.marketresearchfuture.com/sample_request/5582

Rising prevalence of various types of cancer such as breast cancer, melanoma, colon cancer and growing emphasis on women healthcare are the major drivers for the growth of the market. Additionally, increasing number of health problems women further fuel the market growth. Demand for diagnosis and treatment of breast cancer and the technologically advanced medical device is found to be increasing across the globe.  Furthermore, increasing healthcare expenditure and overall growth of healthcare industry also influence the market growth. Extensive research in the field of reproductive health and diseases also boost the market. Increasing demand for new products and accessories with advent of technology in the healthcare industry also fuels the growth of the market across the globe. However, various factors restrained the market growth such as complications associated with the biopsy and unawareness among women.

The global sentinel node biopsy market is expected to grow at a CAGR of 5.1% during the forecast period.

Regional Analysis of the Global Sentinel node biopsy Market             

America captures the first position in the market for sentinel node biopsy whose market is driven by increasing number of women suffering from breast disorders and rising prevalence of breast cancer in the U.S. and Canada. Furthermore, the market is also driven by the availability of technologically advanced medical devices and quality care in healthcare institutes. In Americas, North America is the major market due to increasing number of market players offering biopsy devices and instruments. As per the American Cancer Society, in 2015, there were 231,840 new cases of breast cancer, and till March 2017, there were 3.1 million women with a history of breast cancer in the U.S. As per the National Cancer Institute, 2016, in the U.S. around 1,685,210 new cases of cancer were diagnosed and in 2014, around 15,780 children and adolescents ages 0 to 19 were diagnosed with cancer and 1,960 died of the disease.

In Europe, sentinel node biopsy market shows better growth opportunities governed by the ongoing research and development activities in the field of oncology. In Europe, there is an increasing demand for medical devices and availability of funds for research and development activities in the reproductive health. Germany acquires the first position the European market owing to an increasing demand for cancer diagnosis. France and U.K secure second and third position are respectively owing to the availability of tertiary care facilities in these countries and rising healthcare expenditure.

The Asia Pacific is the fastest growing region in the market whose growth is determined by the presence of highly skilled workforce and increasing demand for biopsy procedures in hospitals and specialty care centers. India and China exhibit enormous growth opportunities owing to ever increasing the prevalence of chronic diseases, increase in a number of women suffering for reproductive disorders, and increasing expenditure on surgical procedures industry by key players in developing economies throughout the Asia Pacific.

In the Middle East, Saudi Arabia and the United Arab Emirates are the major countries holding the largest sentinel node biopsy market share in the market. Increase in the number of specialty care services and rising demand for diagnosis of various types of cancer are the key drivers of the market. Africa exhibits slow growth owing to limited penetration of technology in this region and unawareness about sentinel node biopsy.

Segments                                                                                                                                            

The global sentinel node biopsy market is segmented on the basic product, indication, and end user.

On the basis of product, market is segmented into breast localization wire, tissue marker, gamma probe, drainage catheter, and others

On the basis of indication, the market is segmented into breast cancer, melanoma, colon cancer, esophageal cancer, and others.

On the basis of the end user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Healthcare IT Companies
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Key Players in the Global Sentinel Node Biopsy Market          

Some of the key players in this market are Devicor Medical Products, Inc., part of Leica Biosystems. (Germany), C. R. Bard, Inc. (U.S.), INTRAMEDICAL IMAGING LLC (U.S.), Hilfe Engineering Corporation (India), Surgic Eye (Germany), KUB Technologies, Inc. (U.S.), Navidea Biopharmaceuticals, Inc.(U.S.) and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/sentinel-node-biopsy-market-5582

Hematocrit Test Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

 Also known as packed-cell volume (PCV) test, hematocrit test is used to measure the percentage of Red Blood Cells (RBCs) in the blood. The major function of the RBCs is to carry blood throughout the body. The test is usually performed to diagnose various diseases such as anemia, leukemia, lymphoma, congenital heart disease, and others. The test determines the elevation in the percentage of normal RBCs which is 38.8%-50% in men and 34.9%-44.5% in women. The hematocrit test is one of the tests included under complete blood count (CBC) test.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5553

Cardiovascular diseases, cancer, and kidney diseases are increasing the economic burden of various developing and developed nations across the globe. The market for hematocrit test is driven by rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, and others along with changing lifestyle, and increasing demand for diagnostic devices for cardiovascular diseases. However, limited number of trained personnel has restrained the growth of the market. However, the high cost of diagnosis and treatment of cardiovascular diseases also restrains the growth of the market. As per the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the overall prevalence of Chronic Kidney Disease (CKD) in the general population across the globe is nearly 14%. However, the growth of the market is restrained by the inaccurate or misleading result of the test and unawareness about hematocrit test in the diagnosis of the disease.

The global hematocrit test market is expected to grow at a CAGR of 4.5% during the forecast period.

Segments                                                                                                                                          

The global hematocrit test market is segmented on the basis of product, indication, devices, and end-user.

On the basis of product, the market is segmented into the analyzer, hematocrit test meter, and others.

On the basis of indication, the market is segmented into anemia, leukemia, lymphoma, congenital heart disease, kidney tumor, and others.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, and others.

Intended Audience

• Medical Device Manufacturers
• Medical Device Suppliers
• Medical Research Laboratories
• Research and Development (R&D) Companies
• Market Research and Consulting Service Providers
• Potential Investors

Regional Analysis of the Global Hematocrit Test Market                      

The global hematocrit test market consists of four major regions namely, the Americas, Europe, Asia Pacific and the Middle East & Africa, with the Americas capturing the largest market share. The growth of the market is attributed to an increase in the demand for diagnostic procedures, and rising importance of hematology testing for the diagnosis of various chronic diseases. North America accounts for the major share in the American hematocrit test market which is attributed to extensive use of hematocrit test with other diagnostic tests. According to the Center for the Disease Control and Prevention (CDC), as of 2012, nearly half of all the adults, 117 million population in the U.S. had one or more chronic health conditions. One in four adults were diagnosed with two or more chronic health diseases.

In Europe, the growth of the market is driven by increasing demand for diagnostic devices and instrument in hospitals and diagnostic centers. Germany, the U.K, and France are the major contributors to the growth of the market owing to an increase in the number of key players engaged in the manufacturing of medical devices and instruments and rising expenditure in research and development by these major economies. Additionally, well-developed healthcare sector, ever-increasing patient population and high healthcare expenditure by the European nations fuel the market growth.

The Asia Pacific is expecting the fastest growth in the market due to the flourishing growth of healthcare industries in developing economies such as India. Additionally, the ever-increasing prevalence of kidney diseases and cardiovascular diseases and rising demand for quality devices in the healthcare sector is expected to lead the use of advanced equipment, which, in turn, may speed up the market growth in the region. Rising geriatric population with chronic diseases further creates the economic burden on the developing nations thereby accelerating the market growth.

The Middle East & Africa hold the least hematocrit test market share in the market. The market in this regions exhibits steady growth owing to an increase in the demand for the diagnostic and treatment services.  In the Middle East and Africa, the United Arab Emirates (UAE) hold the largest market share owing to the availability of diagnostic and treatment services. Africa shows slow growth due to low technology penetration in developing countries.

Key Players in the Global Hematocrit Test Market         

Some of the key players in this market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Siemens AG (Germany), Beckman Coulter, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Horiba, Ltd. (Japan), Mindray Medical International Limited (China), Boule Diagnostics AB (Sweden), Nihon Kohden Corporation (Japan), Sysmex Corporation (Japan), and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/hematocrit-test-market-5553

Global Dravet syndrome Market 2020 Industry Key Players, Trends, Sales, Supply, Demand, Analysis & Forecast By 2027

 Dravet syndrome is a rare genetic epileptic encephalopathy that begins during the first year of life in an otherwise healthy infant. According to the National Center for Advancing Translational Sciences, in 15% to 25% cases of the Dravet syndrome, a family history of epilepsy or febrile seizures exists. It is also reported that 85% cases of Dravet syndrome originated due to a mutation in the SCN1A gene.

It is noted that development of new drugs and therapies, and rising R&D expenditure are propelling the growth of the market. In recent years, Dravet syndrome has gained significant attention due to the upcoming drugs for its treatment. For instance, on February 06, 2018, Zogenix, Inc. received breakthrough therapy designation from FDA for its product, ZX008. The drug is specialized for the treatment of Dravet syndrome and its related complications.

Get Sample Copy @ https://www.marketresearchfuture.com/sample_request/5509

Various other factors such as unmet medical needs, increasing government assistance, rising healthcare expenditure in the developed countries, improving regulatory framework, increasing adoption rate, and rising funding and reimbursement policies are continuously contributing to the growth of the global Dravet syndrome market.

Despite these drivers, there are some issues associated with Dravet syndrome market. The side effects of drugs and other therapeutic agents, lack of awareness in the developing countries, and poor healthcare system in low and middle-income countries, may hinder the growth of the market.

It is estimated that the global Dravet syndrome market share is expected to grow at a CAGR of 8.5% during the forecast period of 2017-2023.

Intended Audience:

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Government Research Institute
• Academic Institutes and Universities

Key Players:

Some of key the players in the global dravet syndrome market are Biocodex, Biscayne Neurotherapeutics, Cyberonics, Inc., Epygenix Therapeutics, Inc., GW Pharmaceuticals, plc, INSYS THERAPEUTICS, INC., OPKO Health Inc., Ovid Therapeutics, PTC Therapeutics, Sage Therapeutics, Takeda Pharmaceutical Company Limited, Thermo Fisher Life Technologies, Xenon Pharmaceuticals, Zogenix, Inc, and others.

Segmentation:

The global Dravet syndrome market is segmented on the basis of the type of seizures, diagnosis, treatment & management, and end-user.

On the basis of the type of seizures, the market is classified as myoclonic seizures, atonic seizures, partial seizures, absence seizures, tonic clonic seizures, photosensitive seizures, and others.

On the basis of the diagnosis, the market is classified as magnetic resonance imaging (MRI), electroencephalography (EEG), SCN1A testing, and others.

On the basis of the treatment & management, the market is classified as seizure medications, ketogenic diet, vagus nerve stimulation (VNS), and others. The seizure medications segment is further classified into clobazam, stiripentol, sodium valproate, and others.

On the basis of the end-user, the market is segmented into pharmaceutical companies, hospitals, diagnostic laboratories, academic and research institutes, and others.

Browse More Details of the Report @

@ https://www.marketresearchfuture.com/reports/dravet-syndrome-market-5509

Parathyroid Disorders Market Growth, Trends and Value Chain 2020-2027

 Parathyroid glands produce and secrete a parathyroid hormone which is involved in regulation of calcium and phosphorus metabolism. Hyperparathyroidism and Hypoparathyroidism are the two most common parathyroid disorders. The hyperparathyroidism is characterized by an excessive secretion of parathyroid hormone. The most common signs and symptoms of the disorder include kidney stones, bone and joint pain, fragile bones, weakness.

It is estimated that the parathyroid disorders market size is expected to grow at a CAGR 6.5% during the forecast period of 2017-2023.

According to a study published in the Turkish Journal of Trauma and Emergency Surgery in 2016, it is found that hyperparathyroidism is the third most common clinical endocrine disorder with a prevalence between 0.1–1.0%, and an incidence of around 28 cases per 100,000 individuals. It also reported that the incidence rate is highest between 50 and above age group i.e. the condition is affecting 2% of the population aged 55 years or older.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5451

Notably, rising prevalence of parathyroid disorders and growing geriatric population are the key factors driving the parathyroid disorders market.

Various other factors such as increasing incidences of parathyroid disorders, increasing government assistance, rising healthcare expenditures, improving regulatory framework, and rising funding and reimbursement policies are continuously contributing to the growth of the global parathyroid disorders market. According to the data suggested by Eurostat, it is observed that among the EU Member States, the highest value of healthcare expenditure was recorded in Germany in 2014 i.e. EUR 321 billion, which is further followed by France with EUR 237 billion, and the United Kingdom with EUR 223 billion.

Despite these drivers, there are some issues associated with parathyroid disorders market. Some of the challenges include less research and development funding, side-effects of treatment, the presence of misbranded and spurious drugs, expiration of patented drugs and poor healthcare system in low and middle-income countries may hinder the growth of the market to an extent.

Intended Audience:

• Pharmaceutical Companies
• Research and Development (R&D) Companies
• Medical Device Companies
• Diagnostic Laboratories
• Government Research Institute
• Academic Institutes and Universities

Segmentation

The global parathyroid disorders market is segmented on the basis of type, diagnosis, treatment, and end-user.

On the basis of the type, the market is classified as hyperparathyroidism (HPT), parathyroid cancer, and hypoparathyroidism. The hyperparathyroidism is further segmented into primary hyperparathyroidism, secondary hyperparathyroidism, and tertiary hyperparathyroidism.

On the basis of the diagnosis, the market is classified as blood tests, imaging tests, and urine tests. The imaging tests is further sub-segmented into CT or CAT (computed axial tomography) scans, MRI (magnetic resonance imaging) scans, X-ray, ultrasound, bone density test, and sestamibi scan.

On the basis of the treatment, the market is classified as surgery, radiation therapy, drugs, and others. The drugs segment is further sub-segmented into calcimimetics, hormone replacement therapy, and bisphosphonates.

On the basis of the end-user, the market is segmented into hospitals & clinics, diagnostic centers, drug stores, pharmacies, and others.

Regional Analysis:

The Americas dominate the global parathyroid disorders market owing to the rising prevalence of parathyroid disorders and high healthcare expenditure. According to the Centers for Disease Control and Prevention in 2015, the total health expenditure in the United States was reported to be USD 3.2 trillion and hospital care accounted for a share of 32.3%.

Europe holds the second position in the parathyroid disorders market. It is expected that the support provided by the government bodies for research & development and improvement in the reimbursement policies in the healthcare is likely to drive the market of the European region.

The Asia Pacific region is the fastest growing parathyroid disorders market owing to a huge patient pool and developing healthcare technology. Healthcare expenditure is also improving in various Asia Pacific countries. According to the Australian Institute of Health and Welfare in the years 2015-2016, the total health expenditure was USD 170.4 billion, which is 3.6% higher than the expenditure of 2014-2015.

The Middle East & Africa holds the least market share due to lack of technical knowledge and poor medical facilities.

Key Players

Some of the key players in the global parathyroid disorders market are Abbott Laboratories, Alcon Laboratories, Inc., Amgen Inc., Bayer Healthcare, Becton, Dickinson and Company, Eli Lilly, Ethicon, Inc., Genentech, Medtronic, Merck, Mylan Laboratories, Novartis, Novo Nordisk, Pfizer, Roche, Smith & Nephew plc, Stryker, Teva Pharmaceutical Industries Ltd., Zimmer Biomet Holdings, Inc., and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/parathyroid-disorders-market-5451

Necrotizing Fasciitis Market: Recent Industry Trends and Projected Industry Growth, 2020– 2027

 Also known as flesh-eating disease, necrotizing fasciitis is a rare bacterial infection affecting the tissue beneath the skin, surrounding muscles, and organs. The bacteria that is responsible for the disease releases toxins results into the damage nearby tissue. There are four major types for necrotizing fasciitis – type I known as polymicrobial infection, type II caused by haemolytic group A streptococcus, staphylococci such as methicillin resistant strains/MRSA, type III caused by bacterium such as clostridium, and others. It starts as a minor injury such as a small cut, but may get worst and can be life threatening if left untreated. Major risk factors for the disease are diabetes, cancer, obesity, intravenous drug use, alcoholism, and peripheral vascular disease. The disease can be prevented by maintaining hygiene which includes proper wound care and hand washing.

Browse Sample of the Report @  https://www.marketresearchfuture.com/sample_request/5450

 The global necrotizing fasciitis market is majorly driven by the increasing prevalence of cancer, diabetes, continuously increasing geriatric population and increasing number of patients suffering from various bacterial infection. However, the growth of the market is restricted due to lack of awareness about necrotizing fasciitis and high cost of treatment.

The global necrotizing fasciitis treatment market is expected to grow at a CAGR of 6.2% during the forecasted period.

Segments 

• The global necrotizing fasciitis market is segmented on the basis of type, treatment, and end users.

• On the basis of the type, the market is categorized into Type I, Type II, Type III and others.

• On the basis of the treatment, the market is segmented into intravenous antibiotics, surgery, hyperbaric oxygen treatment and others.

• On the basis of the end users, the market is segmented into hospitals & clinics, surgical centers and others.

Regional Analysis

America accounts for the largest share in the global necrotizing fasciitis market owing to presence of key players in the market and rising emphasis on diagnosis and treatment of rare diseases. Furthermore, rising awareness about bacterial infection is further set to accelerate the growth of the market. North America is the accounted for the highest market share in this region with the U.S. being the largest market followed by Canada. In the U.S, the prevalence of cardiovascular disease is found to be increasing from last few years. This is attributed to the rising prevalence of chronic diseases such as obesity and diabetes which are the major risk factors for cardiovascular diseases. As per the Center for Disease Control & Prevention (CDC), in 2015, 28.4 million adults were diagnosed with cardiovascular diseases in the U.S. alone.

Europe is the second largest market and holds a noticeable share in the global necrotizing fasciitis market. The European market is expected to grow significantly during the forecast period owing to availability of advanced treatment facilities and skilled medical professionals. Furthermore, extensive research and development activities for the treatment of rare disease and increasing government support.

Asia Pacific is expected to be the fastest growing market. Increasing prevalence of chronic diseases such as diabetes, cancer and bacterial infection in developing countries is the major driver for the market growth. China and India are the fastest growing regions owing to increasing geriatric population. Also, the diabetes is one of the major chronic conditions affecting large number of patients, thereby influencing the market growth. Rising awareness about the infections and availability of new treatment methods drive the market in this region. Rising healthcare expenditure and overall growth of healthcare diagnostic and treatment industry also drive the market. According to the International Diabetic Federation, about 415 million people had diabetes across the globe in 2015, which is expected to reach 642 million by 2040. It also stated that 98.4 million and 65.1 million diabetic population lived in China and India, respectively. It stated that in 2015, 3.7% of the Asian population was diagnosed with chronic heart disease, while 21% of the population had hypertension

The Middle East & Africa is expected to show the least growth in the market due to some major factors such as lack of awareness about necrotizing fasciitis, limited access and availability of treatment facilities. In the Middle East, United Arab Emirates holds the largest market share owing to development of healthcare industry and rising availability of specialty care centers.

Key Players

Some of the key players in necrotizing fasciitis market are Merck & Co. (U.S.), WOCKHARDT (India), Atox Bio (Israel), Teva Pharmaceutical Industries (Israel), Basilea Pharmaceutica Ltd. (Switzerland), and MELINTA THERAPEUTICS, INC. (U.S.)

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/necrotizing-fasciitis-market-5450